Compare Sana Biotechnology Inc (SANA) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Target Corporation — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Target Corporation trades at $154 (market cap $69.17B). The key difference: Target Corporation is far larger — about 61.2× Sana Biotechnology Inc's market cap, and Target Corporation pays a 3.05% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TGT | |
|---|---|---|
Market Cap | $1.13B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $152.35 |
52-Week Low | $2.68 | $83.68 |
Enterprise Value | $1.05B | $84.47B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Target Corporation (TGT) trades at $153.50, up 0.93% today, with strong technical momentum and bullish moving averages. Recent earnings beats and the appointment of a Chief AI Officer highlight operational strength. The stock is near its 52-week high, supported by positive analyst sentiment and consistent dividend payments.
Outlook remains positive with solid fundamentals and growth initiatives, though overbought technical indicators and competitive retail pressures pose risks. Revenue stability and margin improvements are key drivers, but investor caution is warranted near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
